|
HK1201851A1
(en)
|
2011-11-11 |
2015-09-11 |
瑞纳神经科学公司 |
Antibodies specific for trop-2 and their uses
|
|
PT3327027T
(pt)
|
2011-11-17 |
2021-02-15 |
Pfizer |
Péptidos citotóxicos e seus conjugados de anticorpos e fármacos
|
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
WO2013092998A1
(en)
*
|
2011-12-23 |
2013-06-27 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
WO2014009426A2
(en)
*
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
US9834597B2
(en)
|
2012-09-21 |
2017-12-05 |
The Regents Of The University Of California |
Modified FC polypeptides, FC conjugates, and methods of use thereof
|
|
RU2618523C2
(ru)
|
2012-11-05 |
2017-05-04 |
Пфайзер Инк. |
Аналоги сплицеостатина
|
|
BR112015010436A2
(pt)
|
2012-11-07 |
2017-08-22 |
Pfizer |
Anticorpos anti-notch3 e conjugados anticorpo-fármaco
|
|
WO2014072482A1
(en)
*
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
EP2968239B1
(en)
|
2013-03-14 |
2019-04-24 |
The University of Massachusetts |
Methods of inhibiting cataracts and presbyopia
|
|
WO2014140300A1
(en)
|
2013-03-15 |
2014-09-18 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
MX368258B
(es)
|
2013-03-15 |
2019-09-25 |
Zymeworks Inc |
Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
|
|
FR3005051A1
(fr)
*
|
2013-04-25 |
2014-10-31 |
Pf Medicament |
Derives de la dolastatine 10 et d'auristatines
|
|
WO2014176696A1
(en)
|
2013-04-30 |
2014-11-06 |
Université de Montréal |
Novel biomarkers for acute myeloid leukemia
|
|
PL2991683T3
(pl)
|
2013-05-02 |
2020-03-31 |
Glykos Finland Oy |
Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
|
|
EP3003387A1
(en)
*
|
2013-06-04 |
2016-04-13 |
Cytomx Therapeutics Inc. |
Compositions and methods for conjugating activatable antibodies
|
|
WO2014202773A1
(en)
*
|
2013-06-20 |
2014-12-24 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
KR20160042871A
(ko)
*
|
2013-06-21 |
2016-04-20 |
이나뜨 파르마, 에스.아. |
폴리펩티드의 효소적 콘쥬게이션
|
|
EP2818867A1
(en)
|
2013-06-27 |
2014-12-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies conjugated to at least one nucleic acid molecule and their use in multiplex immuno-detection assays
|
|
EP3016973A1
(en)
|
2013-07-05 |
2016-05-11 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
|
|
CN105593238B
(zh)
|
2013-07-11 |
2020-09-08 |
诺华股份有限公司 |
使用微生物转谷氨酰胺酶进行赖氨酸特异性化学酶法蛋白质修饰
|
|
CA2919583C
(en)
*
|
2013-07-31 |
2018-09-11 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates
|
|
WO2015015401A2
(en)
|
2013-08-02 |
2015-02-05 |
Pfizer Inc. |
Anti-cxcr4 antibodies and antibody-drug conjugates
|
|
EP3065780A1
(en)
|
2013-11-04 |
2016-09-14 |
Pfizer Inc. |
Anti-efna4 antibody-drug conjugates
|
|
AU2014373593B2
(en)
|
2013-12-23 |
2020-07-16 |
Zymeworks Bc Inc. |
Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
|
|
EP3086813B9
(en)
*
|
2013-12-23 |
2023-09-27 |
Covalab |
Mtg substrates for covalent conjugation of compounds
|
|
CA2935077C
(en)
|
2013-12-27 |
2022-03-15 |
Geoffrey C. Winters |
Sulfonamide-containing linkage systems for drug conjugates
|
|
KR101871088B1
(ko)
|
2014-01-27 |
2018-06-25 |
화이자 인코포레이티드 |
이관능성 세포독성제
|
|
UA120364C2
(uk)
|
2014-04-25 |
2019-11-25 |
Пьєр Фабр Медікамент |
Кон'югат антитіла до igf-1r з лікарським засобом
|
|
PL3134125T3
(pl)
|
2014-04-25 |
2020-04-30 |
Pierre Fabre Médicament |
Koniugat przeciwciało-lek i jego zastosowanie do leczenia raka
|
|
SI3134127T1
(sl)
*
|
2014-04-25 |
2020-06-30 |
Rinat Neuroscience Corp. |
Konjugati zdravil s protitelesi z visoko stopnjo zdravila
|
|
PT3137114T
(pt)
|
2014-04-30 |
2021-02-26 |
Pfizer |
Conjugados anticorpo-fármaco anti-ptk7
|
|
EP4082564A1
(en)
|
2014-06-12 |
2022-11-02 |
CSPC Megalith Biopharmaceutical Co., Ltd. |
Homogenous antibody drug conjugates via enzymatic methods
|
|
AU2015282627B2
(en)
|
2014-06-30 |
2020-04-02 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016020799A1
(en)
|
2014-08-06 |
2016-02-11 |
Rinat Neuroscience Corp. |
Methods for reducing ldl-cholesterol
|
|
EP3185908B1
(en)
*
|
2014-08-28 |
2020-04-15 |
Pfizer Inc |
Stability-modulating linkers for use with antibody drug conjugates
|
|
US11566082B2
(en)
|
2014-11-17 |
2023-01-31 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
ES2764299T3
(es)
|
2014-12-09 |
2020-06-02 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales humanos contra AXL
|
|
CA2971402C
(en)
*
|
2014-12-19 |
2023-08-01 |
F. Hoffmann-La Roche Ag |
Microbial transglutaminases, substrates therefor and methods for the use thereof
|
|
CN107257802B
(zh)
|
2014-12-19 |
2021-11-23 |
豪夫迈·罗氏有限公司 |
转谷氨酰胺酶底物的鉴别及其用途
|
|
US11054425B2
(en)
|
2014-12-19 |
2021-07-06 |
Roche Sequencing Solutions, Inc. |
System and method for identification and characterization of transglutaminase species
|
|
US10676773B2
(en)
|
2015-03-10 |
2020-06-09 |
Bristol-Myers Squibb Company |
Antibodies conjugatable by transglutaminase and conjugates made therefrom
|
|
KR102046862B1
(ko)
|
2015-03-20 |
2019-11-20 |
화이자 인코포레이티드 |
Cti 약물작용발생단을 함유하는 이관능성 세포독성제
|
|
ES3012402T3
(en)
|
2015-04-13 |
2025-04-09 |
Pfizer |
Therapeutic antibodies and their uses
|
|
WO2016170447A1
(en)
|
2015-04-24 |
2016-10-27 |
Rinat Neuroscience Corp. |
Recombinant microbial transglutaminases
|
|
ES2855998T3
(es)
|
2015-08-07 |
2021-09-27 |
Merck Patent Gmbh |
Etiqueta transglutamina para bioconjugación específica de sitio eficiente
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
|
ES2745291T3
(es)
*
|
2015-11-13 |
2020-02-28 |
Univ Massachusetts |
Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia
|
|
TWI778491B
(zh)
|
2015-11-30 |
2022-09-21 |
美商輝瑞股份有限公司 |
位點專一性ｈｅｒ２抗體藥物共軛體
|
|
TWI703160B
(zh)
|
2015-11-30 |
2020-09-01 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
BR112018012055A2
(pt)
*
|
2015-12-15 |
2018-12-04 |
Hoffmann La Roche |
substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
|
|
NZ742916A
(en)
*
|
2015-12-18 |
2023-03-31 |
Eisai R&D Man Co Ltd |
C-terminal lysine conjugated immunoglobulins
|
|
WO2017120536A1
(en)
|
2016-01-08 |
2017-07-13 |
Apg Therapeutics, Inc. |
Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof
|
|
DK3405490T3
(da)
|
2016-01-21 |
2022-01-10 |
Pfizer |
Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
|
|
CA3012960A1
(en)
|
2016-02-01 |
2017-08-10 |
Pfizer Inc. |
Tubulysin analogs and methods for their preparation
|
|
EP3419670A2
(en)
|
2016-02-26 |
2019-01-02 |
Regeneron Pharmaceuticals, Inc. |
Optimized transglutaminase site-specific antibody conjugation
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
WO2017162678A1
(en)
|
2016-03-22 |
2017-09-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Humanized anti-claudin-1 antibodies and uses thereof
|
|
ES2909833T3
(es)
|
2016-05-11 |
2022-05-10 |
Cytiva Bioprocess R & D Ab |
Método de limpieza y/o desinfección de una matriz de separación
|
|
US10654887B2
(en)
|
2016-05-11 |
2020-05-19 |
Ge Healthcare Bio-Process R&D Ab |
Separation matrix
|
|
US10703774B2
(en)
|
2016-09-30 |
2020-07-07 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
JP7031934B2
(ja)
|
2016-05-11 |
2022-03-08 |
サイティバ・バイオプロセス・アールアンドディ・アクチボラグ |
分離マトリックス
|
|
US10730908B2
(en)
|
2016-05-11 |
2020-08-04 |
Ge Healthcare Bioprocess R&D Ab |
Separation method
|
|
US11708390B2
(en)
|
2016-05-11 |
2023-07-25 |
Cytiva Bioprocess R&D Ab |
Method of storing a separation matrix
|
|
EP3455243B1
(en)
|
2016-05-11 |
2021-03-24 |
Cytiva BioProcess R&D AB |
Separation matrix
|
|
US10889615B2
(en)
|
2016-05-11 |
2021-01-12 |
Cytiva Bioprocess R&D Ab |
Mutated immunoglobulin-binding polypeptides
|
|
PE20190340A1
(es)
*
|
2016-06-10 |
2019-03-07 |
Eisai Randd Man Co Ltd |
Inmunglobulinas conjugadas con lisina
|
|
EP3272864A1
(en)
|
2016-07-20 |
2018-01-24 |
Paul Scherrer Institut |
Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
|
|
US11712480B2
(en)
|
2016-08-03 |
2023-08-01 |
Pfizer Inc. |
Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
|
|
KR102493853B1
(ko)
|
2016-08-19 |
2023-01-30 |
브리스톨-마이어스 스큅 컴퍼니 |
세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
|
|
US20190248907A1
(en)
|
2016-09-14 |
2019-08-15 |
Merck Patent Gmbh |
Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition
|
|
US12448411B2
(en)
|
2016-09-30 |
2025-10-21 |
Cytiva Bioprocess R&D Ab |
Separation method
|
|
JP7039577B2
(ja)
|
2016-10-17 |
2022-03-22 |
ファイザー・インク |
抗ｅｄｂ抗体および抗体－薬物コンジュゲート
|
|
WO2018075842A1
(en)
|
2016-10-20 |
2018-04-26 |
Bristol-Myers Squibb Company |
Condensed benzodiazepine derivatives and conjugates made therefrom
|
|
BR112019008345A8
(pt)
|
2016-10-25 |
2023-03-07 |
Inst Nat Sante Rech Med |
Anticorpos monoclonais ligados à isoforma transmembrana cd160
|
|
EP3541830A1
(en)
|
2016-11-17 |
2019-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for increasing endogenous protein level
|
|
CA3051038C
(en)
|
2017-01-24 |
2022-07-26 |
Pfizer Inc. |
Calicheamicin derivatives and antibody drug conjugates thereof
|
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
|
BR112019017500A2
(pt)
|
2017-03-03 |
2020-04-14 |
Rinat Neuroscience Corp |
anticorpos anti-gitr e métodos de uso dos mesmos
|
|
AU2018252193B2
(en)
|
2017-04-14 |
2024-12-12 |
Tallac Therapeutics, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
WO2018213335A1
(en)
|
2017-05-16 |
2018-11-22 |
Scalmibio, Inc. |
Activatable antibodies and methods of use thereof
|
|
EP3630841A1
(en)
|
2017-06-02 |
2020-04-08 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
NZ762376A
(en)
*
|
2017-09-19 |
2022-08-26 |
Scherrer Inst Paul |
Transglutaminase conjugation method and linker
|
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
|
PE20201255A1
(es)
*
|
2017-10-27 |
2020-11-16 |
Pfizer |
Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
PE20251579A1
(es)
|
2018-02-01 |
2025-06-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
KR20240067985A
(ko)
|
2018-02-27 |
2024-05-17 |
화이자 인코포레이티드 |
항체 정제
|
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US20210023209A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
US20210024628A1
(en)
|
2018-03-22 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
|
US11485741B2
(en)
|
2018-04-24 |
2022-11-01 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (TLR7) agonists
|
|
KR20230146098A
(ko)
|
2018-05-23 |
2023-10-18 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
|
DK3797121T3
(da)
|
2018-05-23 |
2024-07-08 |
Pfizer |
Antistoffer, der er specifikke for CD3, og anvendelser deraf
|
|
EP3801629A1
(en)
|
2018-05-29 |
2021-04-14 |
Bristol-Myers Squibb Company |
Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
|
|
AU2019295637B2
(en)
|
2018-06-25 |
2022-12-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
De novo design of potent and selective interleukin mimetics
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
JP7618950B2
(ja)
|
2018-09-19 |
2025-01-22 |
インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
|
JP2022512860A
(ja)
|
2018-11-06 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
|
|
JP2022511390A
(ja)
|
2018-11-20 |
2022-01-31 |
ユニバーシティ オブ ワシントン |
分割インターロイキン模倣体およびその使用
|
|
HUE062089T2
(hu)
|
2018-11-30 |
2023-09-28 |
Rao Naik Chetana |
Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások
|
|
US12478686B2
(en)
*
|
2018-12-12 |
2025-11-25 |
Bristol-Myers Squibb Company |
Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
|
|
WO2020120786A1
(en)
|
2018-12-14 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
|
JP7575102B2
(ja)
|
2018-12-21 |
2024-10-29 |
マルチチュード インコーポレーテッド |
Ｍｕｃ１８に特異的な抗体
|
|
WO2020144233A1
(en)
*
|
2019-01-09 |
2020-07-16 |
Vect-Horus |
Transferrin receptor-binding molecules, conjugates thereof and their uses
|
|
CA3128571A1
(en)
|
2019-03-19 |
2020-09-24 |
Paul Scherrer Institut |
Transglutaminase conjugation method with a glycine based linker
|
|
CN114630838A
(zh)
|
2019-05-20 |
2022-06-14 |
法国国家健康和医学研究院 |
新的抗cd25抗体
|
|
CN114206392A
(zh)
*
|
2019-06-10 |
2022-03-18 |
苏特罗生物制药公司 |
免疫调节剂抗体药物偶联物及其用途
|
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
|
EP4114852A1
(en)
|
2020-03-03 |
2023-01-11 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
|
CA3180683A1
(en)
|
2020-05-12 |
2021-11-18 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
CA3182333A1
(en)
|
2020-05-20 |
2021-11-25 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
|
JP2023528017A
(ja)
|
2020-05-26 |
2023-07-03 |
アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
|
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
|
US20230323299A1
(en)
|
2020-08-03 |
2023-10-12 |
Inserm (Institut National De La Santé Et De La Recherch Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
CN112062855B
(zh)
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
|
WO2022056494A1
(en)
|
2020-09-14 |
2022-03-17 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
CN116406302A
(zh)
|
2020-09-18 |
2023-07-07 |
阿拉里斯生物技术股份公司 |
用基于氨基酸的接头的谷氨酰胺转胺酶缀合方法
|
|
CN116323680A
(zh)
*
|
2020-09-29 |
2023-06-23 |
出光兴产株式会社 |
肽标签和包含其的附加有标签的蛋白
|
|
KR20230095070A
(ko)
|
2020-10-22 |
2023-06-28 |
리제너론 파마슈티칼스 인코포레이티드 |
항-fgfr2 항체 및 이의 사용 방법
|
|
PE20231512A1
(es)
|
2020-10-25 |
2023-09-26 |
Araris Biotech Ag |
Medios y metodos para producir conjugados de ligador-anticuerpo
|
|
WO2022103724A1
(en)
|
2020-11-10 |
2022-05-19 |
Regeneron Pharmaceuticals, Inc. |
Selenium antibody conjugates
|
|
KR20230107260A
(ko)
|
2020-11-12 |
2023-07-14 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
Sars-cov-2 스파이크 단백질의 수용체-결합 도메인에 접합되거나 융합된 항체, 및 백신 목적을 위한 이의 용도
|
|
CN118878694A
(zh)
|
2020-11-23 |
2024-11-01 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
|
CA3205280A1
(en)
|
2020-12-23 |
2022-06-30 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
|
|
CN114685657B
(zh)
|
2020-12-31 |
2024-08-16 |
康诺亚生物医药科技（成都）有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
|
MX2023008986A
(es)
|
2021-01-29 |
2023-08-15 |
Inst Nat Sante Rech Med |
Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
|
|
FR3120865B1
(fr)
|
2021-03-19 |
2025-02-28 |
Univ Toulouse 3 Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
|
|
FR3120866B1
(fr)
|
2021-03-19 |
2025-02-28 |
Univ Toulouse 3 Paul Sabatier |
Molécule hybride comprenant un peptide citrulliné dérivé de la fibrine et un anticorps ou fragment d’anticorps se liant à CD38 et/ou CD138, et ses utilisations
|
|
FR3120877B1
(fr)
|
2021-03-19 |
2025-03-14 |
Univ Toulouse 3 Paul Sabatier |
Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations
|
|
WO2022200303A1
(en)
|
2021-03-23 |
2022-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
US20240199750A1
(en)
|
2021-03-26 |
2024-06-20 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
|
US20240382592A1
(en)
|
2021-04-09 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of anaplastic large cell lymphoma
|
|
WO2022223488A1
(en)
|
2021-04-19 |
2022-10-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of splice switching oligonucleotides for exon skipping-mediated knockdown of pim2
|
|
AU2022270880A1
(en)
|
2021-05-03 |
2023-09-28 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
KR20240019297A
(ko)
|
2021-06-09 |
2024-02-14 |
이나뜨 파르마 에스.에이. |
Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022263451A1
(en)
|
2021-06-15 |
2022-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Peptides derived from the spike protein of sars-cov-2 and uses thereof for diagnosis and vaccine purposes
|
|
IL307947A
(en)
|
2021-07-28 |
2023-12-01 |
Regeneron Pharma |
An antiviral compound of proteins
|
|
WO2023052541A1
(en)
|
2021-09-30 |
2023-04-06 |
Imcheck Therapeutics |
Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
|
|
WO2023072934A1
(en)
|
2021-10-25 |
2023-05-04 |
Araris Biotech Ag |
Methods for producing antibody-linker conjugates
|
|
KR20240103030A
(ko)
|
2021-11-17 |
2024-07-03 |
인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 |
범용 사르베코바이러스 백신
|
|
US20250051440A1
(en)
|
2021-12-14 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
EP4201956A1
(en)
*
|
2021-12-23 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Kutzneria albida (kalbtg) transglutaminase used for antibody conjugations
|
|
WO2023137443A1
(en)
|
2022-01-14 |
2023-07-20 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
EP4472740A1
(en)
|
2022-01-31 |
2024-12-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
CN118742328A
(zh)
|
2022-02-22 |
2024-10-01 |
阿拉里斯生物技术股份公司 |
包含两个或更多个有效载荷的肽接头
|
|
CA3254037A1
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer |
MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
JP2025512735A
(ja)
|
2022-03-11 |
2025-04-22 |
リジェネロン ファーマシューティカルズ，インク． |
Ｇｌｐ１ペプチド模倣体を含む抗ｇｌｐ１ｒ抗体係留型薬物コンジュゲートおよびその使用
|
|
EP4508432A1
(en)
|
2022-04-11 |
2025-02-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
IL316140A
(en)
|
2022-05-25 |
2024-12-01 |
Innate Pharma |
NECTIN-4 binding agents
|
|
US20230408497A1
(en)
|
2022-06-20 |
2023-12-21 |
Sysmex Corporation |
Labeled polypeptide, modified polypeptide, production method for these polypeptides, reagent containing these polypeptides, and measurement method for target substance
|
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
|
EP4558823A1
(en)
|
2022-07-22 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
|
JP2025528052A
(ja)
|
2022-07-29 |
2025-08-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法
|
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
|
FR3139820B1
(fr)
|
2022-09-15 |
2025-12-12 |
Univ Toulouse Iii – Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une vascularite auto-immune, et ses utilisations
|
|
FR3139821B1
(fr)
|
2022-09-15 |
2025-12-12 |
Univ Toulouse Iii – Paul Sabatier |
Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations
|
|
WO2024074571A1
(en)
|
2022-10-05 |
2024-04-11 |
Institut National de la Santé et de la Recherche Médicale |
Dc-targeting vaccine against nipah virus infection
|
|
JP2025536268A
(ja)
|
2022-10-12 |
2025-11-05 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｃｄ８１
|
|
EP4619438A2
(en)
|
2022-11-14 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
KR20250128394A
(ko)
|
2022-11-30 |
2025-08-27 |
리제너론 파마슈티칼스 인코포레이티드 |
Tlr7 작용제 및 이의 항체-약물-접합체
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
AU2024273407A1
(en)
|
2023-05-17 |
2025-12-04 |
Centre National De La Recherche Scientifique |
Anti-cathepsin-d antibodies
|
|
WO2024240162A1
(en)
|
2023-05-23 |
2024-11-28 |
Shanghai Allygen Biologics Co., Ltd. |
Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
|
|
WO2025014533A1
(en)
|
2023-07-10 |
2025-01-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
WO2025082990A1
(en)
|
2023-10-15 |
2025-04-24 |
Araris Biotech Ag |
Antibody-drug conjugates using two different types of topoisomerase i inhibitors
|
|
WO2025096921A1
(en)
|
2023-11-03 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025117727A1
(en)
|
2023-11-29 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
WO2025188693A1
(en)
|
2024-03-05 |
2025-09-12 |
Bristol-Myers Squibb Company |
Bicyclic tlr7 agonists and uses thereof
|
|
US20250282786A1
(en)
|
2024-03-05 |
2025-09-11 |
Bristol-Myers Squibb Company |
Tricyclic TLR7 Agonists and Uses Thereof
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025238052A1
(en)
|
2024-05-15 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
|